Sarcopenia Among Patients With Nonalcoholic Fatty Liver Disease (NAFLD) Is Associated With Advanced Fibrosis

Harring, Michael; Golabi, Pegah; Paik, James; Shah, Dipam; Racila, Andrei; Cable, Rebecca; Srishord, Manirath; Younossi, Zobair M.

doi:10.1016/j.cgh.2023.02.013

Cited by 19 publications

(11 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Various studies have demonstrated that LSM is the most effective surrogate marker for predicting unfavorable outcomes in PBC patients and for detecting cirrhosis or severe fibrosis. Recent research has linked sarcopenia to severe liver fibrosis in NAFLD patients ( 27 ). These results indicated that liver fibrosis may have a close relationship with sarcopenia.…”

Section: Discussionmentioning

confidence: 99%

Prevalence and effect on prognosis of sarcopenia in patients with primary biliary cholangitis

Yang,

Jiang,

Fan

et al. 2024

Front. Med.

View full text Add to dashboard Cite

BackgroundSarcopenia adversely affects the treatment outcomes in Cirrhosis and NAFLD. However, such research is limited in primary biliary cholangitis (PBC) patients. This study was performed to examine the prevalence of sarcopenia and its impact on PBC patients’ prognoses.MethodsThis study enrolled confirmed PBC patients who had an abdominal CT scan. Sarcopenia was determined by the L3-skeletal muscle index with a Chinese population-based cut-off value. Laboratory test values and liver stiffness measurements values were obtained from the electronic medical records.ResultsIn total, 174 PBC patients with a median age of 54 (IQR, 48, 62) years old, were enrolled. 45 (25.9%) patients among them were diagnosed with sarcopenia. Univariate and multivariate logistic regression results illustrated that male gender (OR = 9.152, 95%CI = 3.131–26.751, p < 0.001) and LSM ≥ 12.8 kPa (OR = 4.539, 95%CI = 1.651, 12.478, p = 0.003) were the independent risk factors of sarcopenia in PBC patients. In the prognosis analysis, sarcopenia was determined as a risk factor for indicating adverse events in PBC patients (HR = 4.058, 95%CI = 1.955–8.424, p < 0.001) by Cox proportional hazards regression.ConclusionThe current findings illustrate that comprehensive evaluation and management of sarcopenia may contribute to the improvement of treatment outcomes and life quality of PBC patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Prevalence and effect on prognosis of sarcopenia in patients with primary biliary cholangitis

Yang,

Jiang,

Fan

et al. 2024

Front. Med.

View full text Add to dashboard Cite

show abstract

“…In fact, the presence of sarcopenia in people with NAFLD is linked with an almost twofold higher risk for all-cause mortality, a threefold higher risk for cardiac-related mortality, a twofold higher risk for cancer-related mortality, and an 11% higher risk for significant hepatic fibrosis. Indeed, the interaction of NAFLD and sarcopenia accounted for 55% of significant hepatic fibrosis cases ( 52 ). In this context, assessment for sarcopenia and NAFLD in people with type 2 diabetes is important for its prognostic and therapeutic implications.…”

Section: Natural Historymentioning

confidence: 99%

Understanding the Burden of Nonalcoholic Fatty Liver Disease: Time for Action

Younossi,

Henry

2024

Diabetes Spectrum

Self Cite

View full text Add to dashboard Cite

The prevalence of nonalcoholic fatty liver disease (NAFLD) in the United States is 38%, having increased by 50% within the past 3 decades. The estimated NAFLD prevalence among people with type 2 diabetes is 55–70%. The presence of type 2 diabetes is associated with a higher likelihood of progression of NAFLD to fibrosis development, liver transplant, and death. Cardiovascular disease is the main cause of mortality among people with NAFLD, and the risk of death is significantly higher in people with both NAFLD and type 2 diabetes. NAFLD carries high patient and economic burdens but low awareness among both the general public and health care providers. This article reviews the epidemiology of NAFLD and discusses the need for appropriate risk stratification, referral for specialty care, management of cardiometabolic risk factors, and treatment of the disease. The authors present a call to action to raise awareness of NAFLD and address its increasing burden in a systematic and efficient manner.

show abstract

“…Sarcopenia and NAFLD, as prevalent geriatric diseases, have become primary concerns of public health. The occurrence rate of loss of muscle mass and strength is high in NAFLD patients 9. An increasing number of studies have shown that there was an association between sarcopenia and NAFLD,10 which share several risk factors such as obesity, diabetes mellitus, abnormal hormone levels, dietary factors, metabolic syndrome and lack of exercise 11.…”

Section: Introductionmentioning

confidence: 99%

Association between non-alcoholic fatty liver disease and risk of sarcopenia: a systematic review and meta-analysis

Deng,

Ou,

et al. 2024

BMJ Open

View full text Add to dashboard Cite

ObjectivesTo determine the association of non-alcoholic fatty liver disease (NAFLD) with the incidence of sarcopenia.DesignSystematic review and meta-analysis of observational clinical studies.Setting and participantsAdults with NAFLD.MethodsDatabases such as PubMed, Embase, Cochrane and Web of Science were searched for eligible studies published from the inception of each database up to 4 April 2023. All cross-sectional studies on the association between NAFLD and sarcopenia were included in this study. The quality of the included studies and risk of bias was assessed using the Agency for Healthcare Research and Quality checklist. STATA V.15.1 software was used for statistical analysis.ResultsOf the 1524 retrieved articles, 24 were included in this review, involving 88 609 participants. Our findings showed that the prevalence of sarcopenia was higher in the NAFLD group than in the control group (pooled OR 1.74, 95% CI 1.39 to 2.17). In a subgroup analysis by region, patients with NAFLD showed an increased risk of sarcopenia (pooled OR 1.97, 95% CI 1.54 to 2.51) in the Asian group, whereas patients with NAFLD had no statistically significant association with the risk of sarcopenia in the American and European groups, with a pooled OR of 1.31 (95% CI 0.71 to 2.40) for the American group and a pooled OR of 0.99 (95% CI 0.21 to 4.69) for the European group. Similar results were observed in the sensitivity analysis, and no evidence of publication bias was observed.Conclusions and implicationsThe current study indicated a significant positive correlation between NAFLD and sarcopenia, which may be affected by regional factors. This study provides the correlation basis for the relationship between NAFLD and sarcopenia and helps to find the quality strategy of sarcopenia targeting NAFLD.

show abstract

Sarcopenia Among Patients With Nonalcoholic Fatty Liver Disease (NAFLD) Is Associated With Advanced Fibrosis

Cited by 19 publications

References 35 publications

Prevalence and effect on prognosis of sarcopenia in patients with primary biliary cholangitis

Prevalence and effect on prognosis of sarcopenia in patients with primary biliary cholangitis

Understanding the Burden of Nonalcoholic Fatty Liver Disease: Time for Action

Association between non-alcoholic fatty liver disease and risk of sarcopenia: a systematic review and meta-analysis

Contact Info

Product

Resources

About